These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 26546616)
1. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Danial C; Sarin KY; Oro AE; Chang AL Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616 [TBL] [Abstract][Full Text] [Related]
2. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Danhof R; Lewis K; Brown M Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802 [TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Collier NJ; Ali FR; Lear JT Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236 [TBL] [Abstract][Full Text] [Related]
5. [Not Available]. Basset-Seguin N Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683 [TBL] [Abstract][Full Text] [Related]
6. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Chen L; Silapunt S; Migden MR Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494 [TBL] [Abstract][Full Text] [Related]
7. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies. Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888 [TBL] [Abstract][Full Text] [Related]
8. Hedgehog Pathway Inhibition. Sekulic A; Von Hoff D Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418 [TBL] [Abstract][Full Text] [Related]
9. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279 [TBL] [Abstract][Full Text] [Related]
10. Sonidegib for the treatment of advanced basal cell carcinoma. Ramelyte E; Amann VC; Dummer R Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055 [TBL] [Abstract][Full Text] [Related]
11. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy. Buetti-Dinh A; Jensen R; Friedman R BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351 [TBL] [Abstract][Full Text] [Related]
12. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Dessinioti C; Plaka M; Stratigos AJ Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163 [TBL] [Abstract][Full Text] [Related]
14. Sonidegib phosphate: new approval for basal cell carcinoma. Tibes R Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162 [TBL] [Abstract][Full Text] [Related]
15. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. Li Y; Song Q; Day BW Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788 [TBL] [Abstract][Full Text] [Related]
16. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439 [TBL] [Abstract][Full Text] [Related]
17. Sonidegib: First Global Approval. Burness CB Drugs; 2015 Sep; 75(13):1559-66. PubMed ID: 26323341 [TBL] [Abstract][Full Text] [Related]
18. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Proctor AE; Thompson LA; O'Bryant CL Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609 [TBL] [Abstract][Full Text] [Related]
19. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature. Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789 [TBL] [Abstract][Full Text] [Related]
20. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]